N&B analysis was performed from the SNAP signal to determine the oligomerisation of SNAP/FLAG-hGLP-1R after exendin-4 stimulation by assessing the apparent brightness and number of pixels involved using SimFCS 4 software
Exclusion criteria for both cohorts included a type 1 diabetes (T1D) diagnosis, gestational diabetes, metastatic cancer, comorbid conditions related to unintentional weight change, bariatric surgery, pregnancy, and pharmacy claims for anti-obesity medication in the baseline or follow-up periods
Novo Nordisk is examining oral semaglutide in patients with Alzheimer's disease
Anyone pregnant, breastfeeding, or with a diagnosed metabolic, hepatic, or endocrine condition falls entirely outside any studied context and should not be a subject of self-directed use
In fact, multiple studies have demonstrated that semaglutide reduces hepatic steatosis, decreases inflammation, and improves overall liver function, making it a promising therapeutic option for metabolicassociated liver disease [5, 6]